2023年6月5日

聖地亞哥,加利福尼亞,美國聖地亞哥,05年6月,2023年(全球通訊社)——目的性利用生物有限公司(納斯達克:TBIO),一個領導者在分子生物學multi-omic自動化解決方案和合成生物學應用,今天宣布關閉其私人配售的可贖回可轉換優先股和權證導致初始目的性利用生物的總收入為2800萬美元。私募發行的認股權證將為目的性利用生物提供總值約4620萬美元的額外收益如果現金行使。融資是由諾瓦利斯LifeSciences LLC在Northpond企業的參與下,BroadOak Capital Partners和m - 185公司的附屬公司的首席執行官和創始人托德·r·納爾遜博士學位。該公司還宣布任命保羅•邁斯特諾瓦利斯的合夥人LifeSciences LLC公司的董事會後立即關閉。請參考公司的形式公布與美國證券交易委員會(sec)提交的完整的融資。公司打算使用融資所得一般企業用途。這個新聞稿並不構成要約出售或要約購買任何安全的征集。沒有注冊提供的證券在1933年的證券法案,修訂或適用的國家證券法律,不得提供或出售在美國或者任何國家沒有登記證券法案和適用國家證券法律或適用豁免注冊要求。H.C.溫賴特& co .)擔任私人配售的財務顧問。關於目的性利用生物目的性利用生物讓科學家能夠創建小說,合成biology-enabled許多人類最大的挑戰的解決方案。 As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Telesis Bio is enabling rapid, accurate and reproducible writing of DNA and mRNA for numerous downstream markets. The award-winning BioXp® system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. As a result, it delivers virtually error-free synthesis of DNA and RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Telesis Bio is a public company based in San Diego. For more information, visit www.telesisbio.com. Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp are trademarks of Telesis Bio Inc. About Novalis LifeSciences Novalis LifeSciences is a boutique investment and advisory firm for the Life Science industry. With a team of experienced operating executives from the industry, Novalis funds and advises visionary Life Science entrepreneurs. For more information visit www.novalislifesciences.com. Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include statements and guidance regarding the anticipated use of proceeds from the financing, as well as statements regarding the future release and success of new and existing products and services. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled Risk Factors and elsewhere in our Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission (SEC) on March 22, 2023, as amended on May 17, 2023 and in our Quarterly Report on Form 10-Q, which was filed with the SEC on May 12, 2023. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Telesis Bio disclaims any obligation to update these forward-looking statements. Contact: